REFERENCE
Bleeker JS, Syed FF, Cooper LT, Weiler CR, Tefferi A, Pardanani A.Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs. American Journal of Hematology 87: 703-6, No. 7, Jul 2012. Available from: URL: http://dx.doi.org/10.1002/ajh.23120 - USA
Additional information
Key words
Peginterferon-alfa; adverse reactions; Lymphopenia; Elevated-aminotransferase-levels; drug-induced; Muscle-pain; Alemtuzumab; Pneumocystis-pneumonia; Depression; Hypothyroidism
An event is serious (FDA MedWatch definition) when the patient outcome is: death; life-threatening; hospitalisation; disability; congenital anomaly; requires intervention to prevent permanent impairment or damage
Rights and permissions
About this article
Cite this article
Alemtuzumab/peginterferon-α. React. Wkly. 1426, 6 (2012). https://doi.org/10.2165/00128415-201214260-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201214260-00017